Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Susan Bailey Gurley · OREGON HEALTH & SCIENCE UNIVERSITY · 2023 · $119,348 — Project Summary Hypertension affects more than 60 million people in the US and despite its diverse causes, blockade of the renin-angiotensin system (RAS) lowers blood pressure in the majority of hypertensive patients. ACE2 is the newest member of the RAS, and our previous work has established that A…
MARK C CHAPPELL · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2023 · $774,719 — ABSTRACT Hypertension is the leading risk factor for cardiovascular disease, is highly prevalent with high lifetime cumulative incidence rates, and is the leading cause of death compared to any other risk factor. Premature birth is an emerging and important risk factor for hypertension and cardiovas…
Gaya K. Amarasinghe · WASHINGTON UNIVERSITY · 2023 · $638,713 — Project Summary/Abstract This R01 entitled, “Development and characterization of engineered therapeutic antibodies against SARS-CoV- 2”, builds on our project infrastructure, expertise, and experience in characterizing viral-host factor interactions in negative strand RNA viruses. Since originating …
Andrea Lee Frump · INDIANA UNIVERSITY INDIANAPOLIS · 2023 · $780,019 — PROJECT SUMMARY This proposal builds on the scientific premise that right ventricular (RV) maladaptive remodeling is a major contributor to RV failure and mortality in pulmonary hypertension (PH). Despite its importance, no RV-directed therapies exist. The goal of this proposal is to is to identify …
Eric D Lazartigues · LSU HEALTH SCIENCES CENTER · 2023 · $549,262 — With prevalence as high as 55% for individuals aged 55 and older in United States, hypertension (HTN) is a major risk factor contributing to cardiovascular diseases (CVD) and global mortality, hence remaining an increasingly important medical and public health issue. The role of the brain renin-angi…
Yong Huang · UNIVERSITY OF FLORIDA · 2023 · $214,733 — Project Summary The overarching goal of this research is to fabricate an in vitro three-dimensional (3D) human respiratory model with an air-liquid interface (ALI), which can serve as a platform for COVID-19 related biomedical investigations. A recent COVID-19 outbreak, which is due to the infection…
Eric D Lazartigues · LSU HEALTH SCIENCES CENTER · 2023 · $600,541 — With prevalence as high as 55% for individuals aged 55 and older in United States, hypertension is a major risk factor contributing to cardiovascular diseases (CVD) and global mortality, hence remaining an increasingly important medical and public health issue. The role of the renin-angiotensin syst…
Asrar B. Malik · UNIVERSITY OF ILLINOIS AT CHICAGO · 2023 · $730,601 — ABSTRACT Human induced pluripotent stem cells (iPSCs) can be used to generate 3-dimensional lung organoid structures. However, most lung organoid studies have focused on human iPSC-derived lung epithelial subtypes. They have not to date included human iPSC-derived endothelial cells and systematical…
Ekaterina Koroleva · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2023 · $190,161 — Lung immunopathology is a major cause of the morbidity and mortality associated with the SARS-CoV-2 infection. Accumulating evidence suggests that SARS-CoV-2-associated lung damage is caused not only by the virus, but also by excessive production of proinflammatory cytokines, known as cytokine storm…
KATHLEEN E. RODGERS · UNIVERSITY OF ARIZONA · 2023 · $1,528,567 — PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide, and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. In rece…
Jason V Baker · UNIVERSITY OF MINNESOTA · 2023 · $685,031 — ABSTRACT Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) has become a widespread global pandemic. While the predominant clinical manifestation of severe COVID-19 is respiratory failure, other organ complications such as cardiac injury are c…
ALEXEY VLAD ONUFRIEV · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2023 · $303,804 — Project Summary. This proposal responds to PAR-19-253 “Focused Technology Research and Development”. Our main goal is to develop a novel class of implicit solvation models, as accurate, and even more accurate, than standard explicit solvent models, but much faster. The high accuracy, fast implicit s…
KAI ZHAO · OHIO STATE UNIVERSITY · 2023 · $519,430 — Project Summary Since its outbreak in China in December 2019, the global impact of SARS-CoV-2 infection has been extraordinary, with over 350 million cases and more than 5.5 million lives lost (WHO Coronavirus Dashboard, Jan 2022). Despite various public health measures, such as social distancing, …
Qizhi Gong · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $590,077 — RESEARCH SUMMARY Sudden-onset of olfactory loss has been recognized as a common COVID-19 symptom. The mechanism of COVID-19 related olfactory dysfunction is unknown. Whether the degree of olfactory deficit is indicative of any long-term neurological diseases in COVID-19 has not been evaluated. Recen…
Christian Bime · UNIVERSITY OF ARIZONA · 2023 · $153,040 — ABSTRACT The pandemic COronaVIrus disease 2019 (COVID-19) is an infectious disease, which is caused by a novel and highly pathogenic virus strain SARS-CoV-2 (Severe acute respiratory virus syndrome coronavirus 2). The infection may cause severe lower respiratory tract infection with acute respirator…
Matthew J. Flick · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $542,806 — SUMMARY Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; CoV2) is the first highly pathogenic and highly transmissible human coronavirus that is the causative agent for the worldwide COVID-19 pandemic. As of November 2020, 50 million cases of CoV2 infection worldwide and 1.25 million dea…
Sachiko Homma · BOSTON UNIVERSITY MEDICAL CAMPUS · 2023 · $145,723 — PROJECT SUMMARY As the COVID-19 pandemic continues, managing post COVID-19 long-haul symptoms have become the next level challenge. Persistent skeletal muscle aches (myalgia) and fatigue are among the most common symptoms reported by COVID-19 long haulers who have symptoms beyond 20 weeks. The myalg…
Ivan Marazzi · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $695,078 — PROJECT SUMMARY Infection causes inflammation, which contributes to pathogen clearance and survival of the host organism. However, failure to regulate the inflammatory response can often lead to multiple organ damage and lethality for the host. In the current COVID-19 pandemic caused by the severe a…
Christopher L King · CASE WESTERN RESERVE UNIVERSITY · 2023 · $1,004,770 — The duration and nature of humoral immunity to SARS-CoV-2 (CoV2) infection is poorly understood. Most studies have focused on the immune response in patients with clinical illness, but little is known about antibody response to CoV2 regarding the earliest immunological events immediately after expos…
Andrei A Vakhtin · LOVELACE BIOMEDICAL RESEARCH INSTITUTE · 2023 · $737,345 — ABSTRACT: Approximately one third of non-hospitalized coronavirus disease of 2019 (COVID-19) patients report chronic symptoms after recovering from the acute stage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Some of the most persistent and common complaints of this pos…